Neuren Pharmaceuticals Ltd has released a press release.
Quarterly report and cash flow statement for Q3 2020
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
- Q2 2020 Activity Report and Cash Flow Report
- Proposed issue of Securities - NEU
- Neuren successfully completes $20m capital raising
- Temporary enrolment pause ended in Phase 3 trial in the US
Later from Neuren Pharmaceuticals
- Approval received for final stage of NNZ-2591 clinical trial
- Positive opinion for all 3 Orphan applications in Europe
- European Commission grants 3 NNZ-2591 Orphan designations
- Quarterly report and cash flow statement for Q4 2020
- Successful Phase 1 trial for Neurens NNZ-2591
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals